Phase 2 N=120 The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery
Peanut Allergy
Primary: Passing the Week 117 DBPCFC to Peanut — 21; 19; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Compassionate Use Study of Methylnaltrexone
Opioid-induced Constipation
Primary: Number of Participants With Opioid Induced Side Effects — 3; 1; 3; 1 Participants
Phase 2 N=39 Oxytocin as Adjunctive Treatment of Schizophrenia
Schizophrenia
Primary: Eye Tracking: Fixation Count — 6.78; 9.19; 9.88; 7.94 Number of face fixations
N/A N=8 Treatment of RLS/WED Symptoms Through Sensory Counter-stimulation
Restless Legs Syndrome · Willis-Ekbom Disease
Primary: Change in International Restless Legs Syndrome Rating Scale (IRLS) — 19.5 score on a scale — p=0.0396
Phase 2 N=37 Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures
Opioid-induced Constipation
Primary: Percentage of Participants With Laxation Response Within 2 Hours of the First Dose — 33.33; 0 percentage of participants — p=0.0213
Phase 3 N=230 Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1
Hepatitis C Virus (HCV)
Primary: Percentage of Participants in the Modified Intention-to-Treat Population With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 100.0 percentage of…
N/A N=101 Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France
Herpes Zoster
Primary: Evaluation of Herpes Zoster (HZ) and Postherpetic Neuralgia (PHN) Related Direct Medical Costs by Drugs Prescribed. — 10; 1; 3; 0 Participants
Phase 3 N=32 Evaluate Dental Plaque Benefit of a Preventive Treatment Gel
Dental Plaque
Primary: Mean Turesky Modified Quigley-Hein Index at Day 4 — 1.83; 1.96 score on a scale
Phase 3 N=120 Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS
HIV/AIDS
Primary: HIV-1 RNA Viral Load — 37; 72 Participants
N/A N=76 DESIVI: Dosing of Electrical Stimulation in Venous Insufficiency
Varicose Veins · Venous Stasis · Venous Insufficiency
Primary: Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMV — 3.36; 26.58; 39.49; 0.46 percentage change from device off
Phase 4 N=22 Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer
Breast Cancer
Primary: Number of Participants Experiencing at Least One Adverse Event — 15; 5 Participants
Phase 2 N=171 Males, Antioxidants, and Infertility Trial
Male Infertility
Primary: Live Birth Rate — 15.3; 22.1 percentage of live births
Phase 3 N=36 The Insulin-Only Bionic Pancreas Bridging Study
Type1 Diabetes Mellitus
Primary: Mean CGM Glucose — 144.3; 162; 155 mg/dl
Phase 2 N=120 Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
Primary Myelofibrosis (MF) · Post-Polycythemia Vera (PV) MF · Post-Essential Thrombocythemia (ET) MF
Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24 — 38 Participants — p=0.0007
Phase 3 N=1,212 Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
Acne Vulgaris
Primary: Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear) — 255; 157 Participants